Fulgent Genetics, Inc. (FLGT)
Nasdaq: FLGT · Services-Medical Laboratories · El Monte, CA · filing with the SEC since 2016
Who owns Fulgent Genetics, Inc.
As filed with the SECHolders of 5% or more
3
Ming Hsieh holds 32.3% of Common Stock, par value $0.0001 per share, as its SCHEDULE 13D/A filed May 27, 2026 says.
Directors and officers
7
report now, of 12 people on the record since 2016. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 3 named at left.
Holders of 5% or moreshare of the class, as filed
Ming Hsieh
SCHEDULE 13D/A · filed May 27, 2026 · Common Stock, par value $0.0001 per share · 30.7% in Mar 31, 2026
Barclays PLC
SCHEDULE 13G/A · filed May 13, 2025 · COMMON-STOCK · 5.42% in Mar 21, 2025
Blackrock, Inc.
SCHEDULE 13G/A · filed Apr 3, 2025 · Common Stock
Integrated Core Strategies (US) LLC
SCHEDULE 13G/A · filed Feb 4, 2026 · Common Stock, par value $0.0001 per share · reported falling below 5%, from 5.6% in Jul 29, 2025
What FLGT reports owning in othersstakes of 5% or more, and other ties
Other ties the annual report names
ANP Technologies Incorporation
A company bought · acquisition · Jun 2025 · owns, named in the 10-K filed Feb 27, 2026
7 subsidiaries in 3 countries, from the list filed with the 10-K filed Feb 27, 2026.
Insider tradesForm 4
15sales
0purchases
0sales on a scheduled plan
2people selling
$700,000sold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Oct 28, 2025 to Oct 28, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Oct 28, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window2 of 14 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Xie Jian | President and COO | 8 | $500,000 | 0 | 0 | $0 |
| Gao Hanlin | Chief Scientific Officer | 7 | $200,000 | 0 | 0 | $0 |